Skip to main content

RheumNow Podcast – ACR Convergence Begins (11.5.2021)

Dr. Cush reviews the news, and kicks off ACR21 learning and how to take in the annual meeting.

  1. Study 144 pts Rx w/ Rituximab for Autoimmune renal Dz (AAV, FSGS, IgG4RD, LN, etc). 17% had Severe infections (SIE) w/in 3 mos; mostly pulm & GU. Risk factors=BMI, high creatinine. Hypogammaglobulinemia was frequent (58.5%) but not associated with SIE

  2. Early RA cohort (CATCH) 1891 early RA, 30% Rx oral steroids as bridge therapy; but 30% of these did not taper or D/C steroids after 24 mos. Early GC use assoc w/ age, unemployment, high Dz activity, later biologic use.

  3. Systematic review of dietary interventions for RA - 30 RCTs, 1063 pts; Pain was most reported outcome, sporadic studies showed occ. lowering of ESR, CRP, TNF, Plts, Igs, etc. Few studies show Anti-inflammatory diets may effective lowering DAS in RA

  4. Serologically Active, Clinically Quiescent SLE

  5. 2 inactive (86%) #RA pts were treated with checkpoint inhibitors & Immune-related adverse events occurred in 7 (32%; two severe AE) leading to 6/22 D/C. RA flares occurred in 12 (55%); 10/12 Rx with steroids & good response.

  6. Management of Immune-Related Adverse Events - ASCO Guideline 

  7. RheumNowS ACR21 Coverage

Join The Discussion


| Nov 06, 2021 12:14 pm

Congratulations Jack !
Although I am retired from clinical rheumatology practice, I am so impressed with what you have amazingly accomplished with Rheum Now and your ACR podcasts, daily summaries, etc !!! Keep up your great, fantastic, tireless effort ! Best wishes for continued success:)
Alan Kaell
Consult for ACGME NAS Scholarly Activites for GME programs.
Clinical Professor of Medicine, Renaissance SOM SUNY SB (V)
Adjunct Clinical Professor, Zucker SOM Hostra/Northwell (V)

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

The author has no conflicts of interest to disclose related to this subject